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1. INTRODUCTION 
1.1   Pulmonary drug delivery and treatment of respiratory tract infection 
Inhaled therapy for medicinal purposes was used at least 4,000 years ago but using antibiotics 
in pulmonary dosage form takes back to 1948 when Abbot Laboratories developed the aero-
inhaler for inhalation penicillin G powder (Anderson et al., 2005; Sanders, 2007). However 
large-scale therapeutic advance dates back in 1997, when tobramycin for inhalation was 
approved by the U.S. Food and Drug Administration (FDA) for use in patients with cystic 
fibrosis(CF) (Konstan et al., 2011). 
Respiratory tract infections affect people in all ages and are very common (Adi et al., 2010;  
Antoniu and Cojocaru, 2012). Globally, infections of the lower respiratory tract are among the 
top three major causes of morbidity and every year, they can be responsible for approximately 
3.5 million deaths in the world (Andrade et al., 2013; World Health Organization 2008). The 
most common treatment for respiratory infection involves oral or parenteral administration of 
high doses of single or combined antibiotics which can show undesirable side effect because 
of high systemic bioavailability (Pilcer et al., 2013; Hoiby et al., 2011). The ability to deliver 
therapeutic agents to the site of action may allow efficient treatments of infection diseases to 
the respiratory tract and has many advantages over other routes (Gelperina et al., 2005). The 
excessive surface area of the lungs which contains the sufficient capillary vessels lead to a rapid 
absorption and the absorbed drug can directly reach to the blood circulation therefore bypass 
the first- pass metabolism in the liver and can be targeted by non-invasive methods (Sung et 
al., 2007; Wu et al., 2014). Therefore, the delivery of even low concentrations of antibiotics to 
the lung, the site of infection leads to much higher concentrations of antibiotics in the lung, 
while reducing systemic exposure and the risk of toxicity and yields therapeutic effects with 
smaller drug doses than the oral or parenteral route (Yang et al., 2009; Cipolla et al., 2013). 
The other big advantage of using pulmonary dosage form of antibiotics in treatment of chronic 
infections is, that is not associated with pain and this should increase patient comfort and 
compliance, causing promoted treatment outcome, enhance the quality of life, shorten the 
hospitalization period and significantly decrease morbidity and mortality (Littlewood et al., 
2012; Greally et al., 2012). 
Ciprofloxacin is a fluoroquinolone antibiotic, a broad-spectrum synthetic agent. Its main 
mechanism of action is the inhibition of the bacterial enzymes DNA gyrase (topoisomerase II) 
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and topoisomerase IV, thus preventing bacterial DNA from uncoiling and duplicating, leading 
to cell death (Masadeh et al., 2015; LeBel et al., 1988). It has potent and effective activity 
against a wide range of Gram-positive bacteria like Staphylococcus and Bacillus species and 
against most Gram-negative microorganisms like Pseudomonas species, and it is often used in 
the treatment of inhalation anthrax and other lung infections (Zhao et al., 2009; Bolon et al., 
2011). Liposomal ciprofloxacin for inhalation is presently in clinical trials for the treatment of 
respiratory diseases. Dry powder formulations of ciprofloxacin is in the advanced development 
stage (Wilson et al., 2013). 
1.2   Marketed Products 
In considering all of these advantages development of inhaled antibiotics to treat lung infection is a 
largely active field, with five approved products in the USA and further in the late stages of clinical 
progress (Cipolla et al., 2013). However literature background show most of researches and 
investigations of pulmonary dosage form of antibiotics focusing on treatment of CF than 
generally the treatment of respiratory tract infection (O’Sullivan et al., 2009; Davis, 2006). CF 
is an inherited disease caused by different mutations of the transmembrane conductance 
regulator gene, and consequently respiratory failure as follow through of adhesive mucus of 
lungs and chronic inflammation of respiratory tract (Ng et al., 2014). Currently, CF is the 
particular pulmonary infection disease in which inhaled antibiotics have received FDA and 
European Medicines Agency (EMA) approval (Quon et al., 2014). Table I. illustrates the 
products of antibiotics in pulmonary dosage form that are present on the market. 
Table Ⅰ: Marketed Products in pulmonary dosage form of antibiotics 
Name of Products Name of 
antibiotic 
Type of 
pulmonary dosage 
form 
Year Producer Approval Agency 
CAYSTON® Aztreonam Nebulization 2010 Gilead Science FDA 
ARIKAYCE® Amikacin Nebulization 2018 PARI pharma FDA 
TOBI 
PODHALER Tobramycin 
Dry Powder 
Inhalation 2013 Novartis FDA 
TOBI 
NOVARTIS Tobramycin Nebulization 2013 Novartis FDA 
COLONYCIN® Colistimethate Sodium 
Dry Powder 
Inhalation 1982 Teva FDA 
COLOBREATHE Colistimethate Sodium 
Dry Powder 
Inhalation 2012 Teva EMA 
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1.3   Formulation aspects of Dry Powder Inhaler systems  
Concerning the possible dosage forms for pulmonal delivery of antibiotics one can use a wide 
variety of formulations such as dry powder inhalation (DPI). The most important approach of 
DPI is that the time required for delivering each dose is short and even less than one-third the 
time needed for delivering same dose for nebulization and adherence of patients increase 
significantly. This fact is expected to improve patients’ adherence (Geller et al., 2007; 
Westerman et al., 2007). 
DPI formulations have been used for patient treatment more than 60 years but during this 
period, the fundamental formation of DPI have not significantly changed (Weers et al., 2015; 
Islam et al., 2008). DPI have become the first choice of inhaled formulation in European 
countries (Hamishehkar et al., 2012). DPI of antibiotics are more stable, quicker administration 
and have less risk of microbial contamination than parallel liquid formulations  Sousa and 
Pereira, 2014; Blau et al., 2007). 
DPI are formulated micronized drug particles with aerodynamic particle sizes of less than 5µm 
(Islam et al., 2008). The entrance of DPI through the airways and the lung faces with three 
mechanisms for deposition of particles (Heyder et al., 1986). These three mechanisms are: 
impaction, gravitational sedimentation and diffusion (Carvalho et al., 2011).  
• Inertial impaction is defined as inertial particle deposition on a surface airway. It appears 
near bifurcations of the airways driving to the large airways, where there is a large flow rate 
and accelerated changes in the direction of the airflow (Grgic et al., 2004). This mechanism 
is essential for large particles having a diameter bigger than 5 µm and is frequent in the 
upper airways like mouth, pharynx and large airways. The expectation of impaction is 
corresponding to Eq. 1 where ø is the change in direction of the air ways, r is the airways 
radius, V is the airstream velocity, and  is the terminal settling velocity. 
  sin ∅
gr
 
(1) 
• Gravitational sedimentation is determined by its size, density and residence time in the 
airways. This mechanism is important for particles greater than 0.5 µm to 3 µm, in the small 
airways (Newman, 1985). According to stokes law particle settling under gravity, will attain 
a constant terminal settling velocity (Eq. 2.) where ρ is the particle density g is gravitational 
constant, d is the particle diameter and ŋ is the air velocity. 
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(2) 
• Brownian diffusion is produced by concussion and bombardment of small particles with 
molecules in the respiratory tract where the airflow is very low. This mechanism is very 
important for particles smaller than 0.5 µm. Diffusion is inversely is proportional to particle 
size. As stated in Stokes-Einstein equation (Eq. 3.) where D is the diffusion coefficient, 
 
is Boltzmann’s constant, T is the absolute temperature and d is the particle diameter and ƞ 
is viscosity. (Aulton, 2018; Batchelor et al., 1976). 
 
(3) 
Different deposition mechanisms are very important for particles with different size (Hofmann 
et al., 2011). Particles larger than 5 µm will deposit in the upper airways by inertial impaction 
mechanism. Those larger than 1 µm and smaller than 5 µm will deposit by gravitational 
sedimentation in the lower airways and particles smaller than 1 µm will deposit by Brownian 
diffusion in the stagnant air of the lower airways by Brownian diffusion. Particles smaller than 
0.5 µm are too large for Brownian diffusion and too small for impaction or sedimentation and 
finally they were exhaled ineffectively (Heyder et al., 1986). Hence for adequate deposition in 
reach to central and alveolar parts of lung the optimal size of particles is in the region of 1-5 
µm.   
Conventionally DPI has been used as a formulation of micronized drug incorporated in carrier 
excipient (Healy et al., 2014). These carrier excipients such as lactose, mannitol, trehalose and 
so on ... had been applied for prevention of agglutination of particles because these small 
particles (1-5µm) due to high surface free energy tend to stick together. without the presence of 
carrier excipient the surface energy is reduced and the adhesive as well as cohesive forces are overcome, 
nevertheless, the flowability of API particles are limited. (Hickey, 2003). Moreover, DPI of 
antibiotics usually have large therapeutic doses (e.g. between 10 mg and 100 mg of antibiotics) 
thus the carrier causes difficulty in application of DPI due to the increased powder volume and 
the scaling down of the use of antibiotics via pulmonary dosage form (Pilcer et al., 2013). 
Around the last two decades there has been assumed a significant research on the design of 
carrier free system for DPI (Healy et al., 2014). Applying carrier free system enable the 
delivery of high dose antibiotics to the lungs possible by limiting the amount of excipient (Yu 
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et al., 2016). Carrier free formulations can be handled by coated particles by lipids, amino 
acids, polymer and so on or can be applied by mechano-fusion dry coating process (Boraey et 
al., 2013; Raula et al., 2010; Pilcer et al., 2006). Fig. 1 shows the possible mechanisms of 
deposition in the respiratory system by different DPI systems. 
 
Figure 1: Outline of different DPI systems with three particle deposition mechanisms taking 
place within the respiratory tract 
 
1.4   Quality by Design methodology 
Quality by Design (QbD) is a holistic, systematic, risk, science and knowledge based method, 
focusing on extensive preliminary design in order to ensure the quality of medicinal products 
(Yu et al., 2008). The QbD method realizes a modern quality management thinking where the 
different quality requirements define the process’s steps. In this case, risk assessment (RA) is 
considered to be the most accentual part, and the final goal is to ensure the predefined product 
quality. The QbD method can be applied to the entire pharmaceutical production process, or to 
certain parts of it but also in the early research and development phase (Tomba et al., 2013; 
Huang et al., 2009; Zidan et al., 2007; Charoo et al., 2012). Its use in the early developments 
can help in having a time and cost-effective process, in closing the gap between the science 
and the industry, as well as can facilitate the innovation transfer process to introduce new drugs 
to market (Pallagi et al., 2015; Chatterjee et al., 2011).  
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According to the current Regulatory Science philosophy, QbD has to be one of the key elements 
of different pharmaceutical developments. Regulatory agencies (FDA, EMA) strongly 
recommend and welcome new drug applications that include QbD aspects (FDA, 2012; EMA, 
2012). Steps of QbD based development in pharmaceutical technology include the following: 
1. Definition of Target Product Profile (TPP) and its quality indicators (Quality Target Product 
Profile, QTPP). This usually comprises therapeutic requirements and other quality demands 
(EMA/CHMP, 2014).  
2. Identification of Critical Quality Attributes (CQAs) and Critical Process Parameters (CPPs), 
which have critical influence on the desired final product quality. CQAs are generally 
associated with the drug substance, the excipients, the in-process materials or the drug 
product. CPPs are those process parameters which have an impact on the CQAs. The 
selection of the CQAs and the CPPs should be based on previous scientific experience and 
knowledge from relevant literature sources (Yu et al., 2014). 
3. RA is a systematic process of organizing information to support a risk decision(EMA,  2015) 
and is the key activity of the QbD based methodology. RA can be both initial and final, and 
it may be refined afterwards. RA results help to avoid profitless efforts in later phases of the 
development process.   
The entire QbD methodology, including its steps and elements, is presented graphically in Fig. 
2. This graphical illustration is based on the relevant the International Council Harmonization 
(ICH) guideline (EMEA/CHMP, 2009; EMEA/CHMP,1998) and is completed by the authors 
with the “primary knowledge space development” section and the illustration of 
“knowledge/design and control space” relation to help the better understanding. 
In pulmonary drug delivery the main objective of inhalation is to achieve a reproducible and 
high pulmonary deposition. This may be achieved by a successful selection of the composition 
and careful process optimization (Ambrus et al., 2011; Arafa et al., 2007). The aerosolization 
efficiency of a powder for inhalation is highly dependent on the DPI characteristics, such as 
particle size, distribution, shape, and surface properties (Pomázi et al., 2014; Pomázi et al., 
2013).  A new tendency in the development of DPI is the design of carrier-free microparticles 
with a particle size of 3-5 µm as pulmonary drug delivery systems involving different 
excipients and additives (Singh et al., 2005). The additives applied in small amounts in 
microparticles serve to improve physicochemical stability, wettability, dispersibility and 
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aerodynamic properties (Vehring, 2008). DPIs have special formulation and regulatory aspects 
and their design is a highly complex task (Hoppentocht et al., 2014; de Boer et al., 2017). The 
powder formula and the administration manner should be designed parallel, therefore DPI are 
defined as combined products.  
A regulatory and QbD based DPI product development process has several parameters that 
need special attention and critical thinking (EMA/CPMP, 1998; EMA/CHMP, 2006; FDA, 
1994).  Usually these include the following: (1) Drug substance specifications (e.g. particle 
size, particle size distribution, shape, crystallinity etc.). (2) Moisture and temperature 
sensitivity aspects to avoid aggregation. (3) Specifications of the excipients. (4) Packaging 
(delivery device) for uniform dosing and for assuring the fine particle mass. The current 
research examines regulatory science, namely the QbD and RA based thinking in early stage 
pharmaceutical technological development of a DPI form for pulmonary use. 
 
Figure 2: Steps and elements of the QbD methodology completed by the authors and applied 
in the early stage of pharmaceutical development (Pallagi et al., 2016) 
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1.5   DPI Formulation, stress and accelerated stability tests 
One of the key factors involved in optimizing the DPI performance is the precision particle 
because it is one of the most important part of optimizing the DPI performance in order to 
obtain an accurate, consistent and effective drug doses powder formulation. Specifications for 
the approval requirements of new DPI is set by the FDA (FDA, 1998) and the European 
Inhalanda group (Inhalanda, 1998) and their test methods are equilibrated. The product must 
be in appropriate size aimed inhalation in order to be deposited in the respiratory tract. This 
depends on the characteristics of the product and must be assessed. In order to achieve reduced 
particle size to < 5 µm spray drying method has been frequently used (Miller et al., 2016; 
Sosnik and Seremeta, 2015). It is postulated that by manipulation of particle density to produce 
a mean aerodynamic diameter of 1-5 µm (density of < 0.4 g/cm3), the particles larger than 5 
µm are not able to reach and presented to the alveolar space (Telko and Hickey, 2005). 
However, the presence of excipients is also a crucial factor in terms of modifying the surface 
and stabilizing particle size. L-leucine (LEU) an amino-acid, Hydroxypropyl beta cyclodextrin 
(CD), a cyclic oligosaccharide and Polyvinyl alcohol 3-88 (PVA), a synthetic polymer are 
frequently used as excipients in pulmonary drug delivery. LEU can enhance the aerosolization 
behavior of DPI due to decrease the dispersity of particles (Prota et al., 2011). CD can intensify 
the drug distribution in respiratory tract by cause of decreasing the cohesive and adhesive forces 
(Pitha et al., 1986). PVA can decrease the particle size as a result of covering effect of polymer 
(Pomazi et al., 2013). Using ethanol as co-solvent can help to produce micronized systems. 
Belotti et al concluded that the highest lung deposition was reached upon applying a maximum 
of 10% of ethanol beside the excipients (Belotti et al., 2014). Another objective when green 
technology is applied for drug formulation, chemical products and processes are designed, 
manufactured, and disposed with reduced environmental pollution risk and a lower burden of 
hazardous substances (Fujii et al., 2016). Green technology encompasses a group of methods 
and materials, which not generating toxic products. Hence in this field the invention, design 
and application of pharmaceutical products and processes is in direction to decrease or to 
eliminate the use and developing of hazardous substances (Desal, 1981).  
Therefore, the goal of our study was to design a DPI of ciprofloxacin hydrochloride (CIP) in 
the form of a carrier-free system by applying green technology. The next step of our work was 
to test the stability of DPI in high humidity and temperature.  In most of the reported studies, 
formulations were investigated to storage under high RH and temperature for only short periods 
of time (a maximum of 7 days).           
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1.6   Importance of stress and accelerated stability test 
Stability testing is performed to confirm that drug products keep their entire efficacy up to the 
end of their expiration date, and a series of analytical investigations are necessary for this 
purpose (Láng et al., 2015; Rabel et al., 1999; Bajaj et al., 2012). Test results relevant to the 
stability of the product must be in the predefined limits up till the end of the expiration date. 
FDA and the European Inhalanda Group have published their principles for the tests necessary 
for the approval of a new DPI.( Department of Health and Human Services, 1998;  Schumacher 
and Leiner, 2012  et al., 2012). The storage conditions during stability testing are set on the 
basis of the ICH (International Council on Harmonization) Guideline of Stability Testing of 
New Drug Substances and Products Q1A (R2).(To et al., 2004). The ICH Guideline specifies 
the following storage conditions for stress and accelerated tests: 40 ± 2 ºC with 75 ± 5 % RH 
and the duration of storage is 6 months.  
1.7   Cytotoxicity and permeability of DPI in epithelial lung cells 
The cytotoxicity test is one of the biological assessments and screening tests that apply for 
living cells in vivo to detect the cell growth, reproduction and morphological effects by 
pharmaceutical products (Suresh et al., 2012; Marslin et al., 2017). Cytotoxicity assays are 
extensively used by the pharmaceutical research to screen for cytotoxicity in studying of 
compounds. Considering of the sensitive respiratory mucosa and epithelial lung cells, the active 
ingredients likewise excipients need to be examined in appropriate models for collecting data 
about the safe concentration for pulmonary delivery (Horváth et al., 2016). Damage of lung 
epithelial cell will enhance with increasing concentration of product and key point of safety of 
product is that in applicable dose the concentration of active ingredient and excipients have to 
be in safe and normal range (De Barros et al., 2017; Krátký et al., 2017) (Fig. 3). 
Besides active agent excipients can damage epithelial lung cells and during their application 
toxicity often occur. Despite they are necessary for their transport across biological barrier 
(Deli, 2009). The epithelial barriers of the human body are considerable walls for drug delivery 
to the respiratory system (Pohl et al., 2009). In spite of this physical barrier, comprised of the 
mucociliary apparatus, secreted antimicrobial substances which helps to treat infection 
prevents inhaled antimicrobial drug contacting the subepithelial tissue (Deli, 2009). Hence, 
permeability of these barriers could significantly promote the efficacy of the products It is essential to 
prove the diffusion of drug into epithelial lung cells in order to continue the work and further 
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research in vivo for large scale up manufacturing in industry. There are several routes in these 
barriers, which drug permeability is achieved via them (Fig. 4). 
●     by diffusion along the phospholipid bilayer 
●     the transcellular pathways via integral and peripheral protein transporters 
●     the paracellular pathway 
 
 
Figure 3: Relationship between concentration of active agent and effect on living cells 
 
 
Figure 4: Cells in different part of respiratory system including trachea, bronchi, bronchioles 
and alveoli (Camelo et al., 2014) 
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2. AIMS 
As the primary step of this study, the literature background and marketed products of DPI in 
antibiotics was collected. Secondly the introduction of the key elements of QbD approach to 
design dry powder for pulmonary delivery application – was set up. Based on these preliminary 
data, the next objective was to develop a carrier-free co-spray-dried DPI product containing 
the broadb spectrum antibiotic ciprofloxacin (CIP). CIP can be useful for treatment of variety 
of pulmonary infection disease such as those in patients with CF. This development is a novelty 
as QbD approach was applied for designing the experimental part and the development holds 
the possibility of large scale up manufacturing in industry. The design of carrier-free 
microparticles (“green technology”) with large dose of medicine along with minimum amounts 
of excipients is also a new tendency in the development of DPIs. The additives are carried out 
in small-scale amounts in the microparticles in order to build up greater aerodynamic 
performance and physicochemical stability along with least possible cytotoxicity. The main 
steps in our experiments were the following: 
i. Pre-formulation: Identification of important factors for formulation of DPI based on 
carrier-free system by applying green technology based on the QbD approach. Focusing 
on the critical parameters, the practical development, connections and effects among the 
material characteristics, selected production process, investigation methods and final 
product properties in the design phase.   
ii. Formulation: Study of different excipients (polymers, sugars and amino acid) to develop 
the pulmonary formulation with optimal size and superlative respirable fraction. Hence 
analysis the physiochemical properties of formulations. Afterwards investigation in vitro 
release of samples. 
iii. Investigation of the stress and accelerated stability test of co-spray-dried products: 
Investigation influence of the relative humidity (RH) and temperature on the 
physicochemical properties and aerosolization performance of the formulations during 
storage. 
iv. Ex vivo: Determination of the cytotoxicity of samples in epithelial lung cell line culture to 
screen the safety of formulation for pulmonary delivery along with investigation of 
permeability of formulation that one may to promote information on the availability in 
pulmonary formulations.      
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3. MATERIALS AND METHOD 
3.1   Materials 
CIP, a fluoroquinolone-type antibiotic was supplied by Teva Pharmaceutical Works Ltd. 
(Debrecen, Hungary). CIP is a broad spectrum synthetic agent. Its main mechanism of action 
is the inhibition of the bacterial enzymes DNA gyrase (topoisomerase II) and topoisomerase 
IV, thus preventing bacterial DNA from uncoiling and duplicating, leading to cell death. It has 
potent and effective activity against a wide range of Gram-positive bacteria and against most 
Gram-negative microorganisms and it is often used in the treatment of inhalation anthrax and 
other lung infections. (Table II). 
Table II: Properties of the active agent 
 Ciprofloxacin Hydrochloride 
Chemical structure 
                                      
Chemical name 1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid hydrochloride 
Physical properties White to light yellowish powder substance 
Classification A second generations fluoroquinolone antibiotic  
Dosage Forms Oral, Parenteral 
Dose Oral: 500mg     Parenteral: 400mg 
 
Polyvinyl alcohol 3-88 (PVA), a water-soluble synthetic polymer as a coating material was 
purchased from BASF (Cologne, Germany)(Satoh et al., 2014). The amino acid L-Leucin 
(LEU) was obtained from Hungaropharma Ltd. (Budapest, Hungary). This amino acid can be 
co-spray-dried with active compounds to enhance drug aerosolization behavior (Li et al., 2016). 
Hydroxypropyl beta-cyclodextrin (CD), a cyclic oligosaccharide was donated by Cyclolab Ltd 
(Pitha et al., 1986) (Budapest, Hungary) (Table III). 
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Table III: Properties and structure of the excipients 
Excipients Polyvinyl alcohol 3-88 (PVA) l-leucine (LEU) 
Hydroxypropyl beta-
cyclodextrin (CD) 
Chemical structure 
                
         
Physical properties a white powder 
semi-crystalline 
a white crystalline 
powder a white powder 
Applications 
a stabilizing agent 
a microfine coating 
material 
a dispersity enhancer, 
an aerosolization 
performance promoter  
 
drug distribution 
enhancer 
 
3.2   Methods 
3.2.1   QbD method  
As part of the QbD methodology, knowledge space development and RA were performed. To 
illustrate the relevant knowledge and information, an Ishikawa diagram was set up. The 
technical tool used for the RA was LeanQbD® software (QbDWorks LLC, Fremont, CA, USA). 
In the first step, the desired product was defined and the elements of the quality target product 
profile (QTPP) were determined. Next, the critical quality attributes (CQAs) and the critical 
process parameters (CPPs) of the selected production method were identified. CQAs have 
critical influence on the quality characteristics of the final product and CPPs critically influence 
the CQAs and QTPPs. In the following step an interdependence rating was performed among 
the QTPPs and CQAs, and also among the CQAs and CPPs and was categorized on a three-
level scale. The interaction between the elements was described as “high” (H), “medium,” (M) 
or “low” (L). Its dynamism is presented in figures generated by the software. This was followed 
by the probability rating step where CPPs were estimated and categorized on a 10-point scale. 
Finally, Pareto charts were generated, presenting the numeric data and the ranking of each CQA 
and CPP. 
3.2.2   Solubility of CIP at different pH 
Solubility tests of CIP were carried out at 25°C either in a buffer solution (pH =1.2, 3.5, 5.6, 
6.8 and 7.4) or in distilled water (pH =4.4). Solubility was measured by ultraviolet/visible 
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spectroscopy (UV/VIS) spectrophotometry (ATI-UNICAM UV/VIS spectrophotometer, 
Cambridge, UK). The concentration was determined 24 h after filtering the saturated system. 
3.2.3   Preparation of the microparticulate systems and process parameters 
 The significant solubility of CIP in distilled water allows its use as the solvent for spray-drying 
feed solution. Using 10% of ethanol in an aqueous solution is known to decrease the particle 
size because of its fast evaporation during spray drying. Therefore, the feed solution was 
prepared by dissolving 1 gram of CIP using different excipients at different concentrations in 
an aqueous solution containing 10% of ethanol (Table IV). According to   literature 
background about the effects of organic solvent and additives on the habit (size and 
morphology) and aerosolization characteristics of DPI systems, the optimal excipient 
concentration is achieved as shown in Table IV. 
Table IV: Composition of the DPI products containing an optimal concentration of excipients 
No. CIP [g] LEU [g] PVA [g] CD [g] Solvent [ml] 
CIP 1 - - - 50 
CIP_PVA 1 - 0.2 - 50 
CIP_CD 1 - - 0.9 50 
CIP_LEU 1 0.4 - - 50 
CIP_LEU_PVA_CD 1 0.4 0.2 0.9 50 
 
Spray-drying (SPD) is a one-step process through which it is possible to engineer and produce 
particles directly from solutions with a controlled technique. Hence, spray-drying was 
considered to be the appropriate technique to produce a dry powder for inhalation. The spray-
drying process was carried out using a Büchi Mini Dryer B-191 (BÜCHI Labortechnik, Flawil, 
Switzerland); the parameters were optimized as shown in Table V. 
The amount of dry powder yielded was determined between 65% and 70%. Generally during 
the spray-drying procedure nearly 30% of the sample could be lost. So our produced yield 
correlated with the normal sample production’s habit. 
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Table V: Büchi Mini Dryer B-191 parameters for spray-drying procedure 
Inlet temperature 
[°C] 
Outlet 
temperature 
[°C] 
Feed rate  
[ml min-1] 
Aspiration air 
[L h-1] 
Aspiration rate 
[L min-1] 
130 75 5 600 0.065 
 
3.2.4   Particle size analysis 
Particle size distributions of the spray-dried powders were determined by laser scattering using 
Malvern apparatus (Malvern Mastersizer Scirocco 2000; Malvern Instruments Ltd., 
Worcestershire, UK). Air was used as the dispersion medium for the microparticles from the 
entrance to the sample cell. Approximately 500 mg of product was loaded into the feeder tray. 
The dispersion air pressure was fixed to 2.0 bar to determine even if particle attrition had 
occurred. Obscuration between 10.0% and 13.0% was carried out throughout the whole 
measurement duration. The particle size distribution was characterized by the D (0.1), D (0.5) 
and D (0.9) values and the specific surface area. Span values were calculated according to Eq. 
4. A high Span value (> 1) means a broad particle size distribution.  
 =
 (0.9) −  (0.1)
( 0.5)
 
(4) 
3.2.5   Scanning electron microscopy (SEM) 
The morphology of CIP microparticles was investigated by scanning electron microscopy 
(Hitachi S4700; Hitachi Scientific Ltd., Tokyo, Japan) at 10 kV. The samples were gold-
palladium coated (90 s) with a sputter coater (Bio-Rad SC 502; VG Microtech, Uckfield, UK) 
using an electric potential of 2.0 kV at 10 mA for 10 min. The air pressure was 1.3–13.0 mPa. 
3.2.6   Fourier-transform infrared spectroscopy (FT-IR) 
FT-IR spectra were recorded with an FT-IR spectrometer (Thermo Nicolet AVATAR 330; 
LabX Midland, ON, Canada) between 4,000 and 400 cm-1, at an optical resolution of 4 cm-1. 
The sample was mixed with 150 mg of dry KBr in an agate mortar and the mixture was pressed 
to obtain self-supporting disks at 10 tons. 
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3.2.7   X-ray powder diffraction (XRPD) 
The crystal structure of spray-dried powders containing different excipients was characterized 
using an X-ray powder diffraction BRUKER D8 Advance X-ray diffractometer (Bruker AXS 
GmbH, Karlsruhe, Germany). The powder samples were loaded in contact with a plane quartz 
glass sample slide with an etched square and measured with a slit-detector Cu K λI radiation 
(λ = 1.5406 Å) source. Settings were as follow: the samples were scanned at 40 kV and 40 mA 
and the angular range was 3° to 40° 2θ, at a step time of 0.1 s and a step size of 0.007°. The 
crystallinity index (xc) values were calculated based on the Eq. 5 where A marks the area under 
the whole curve: 
 
(5) 
3.2.8   Differential scanning calorimetry (DSC) 
The thermal response of each product was measured using a DSC (Mettler Toledo TG 821e 
DSC Mettler Inc., Schwerzenbach, Switzerland). About 3–5 mg of powder was precisely 
weighed into DSC sample pans which were hermetically sealed and lid pierced. Each sample 
was on equilibrate for 10 min at ambient temperature before being heated to 400°C at a rate of 
5°C/min. Data analysis was performed using the STARe software (Mettler Toledo Mettler Inc., 
Schwerzenbach, Switzerland). 
3.2.9   Aerodynamic particle size analysis  
Aerodynamic particle size distribution was determined using a seven-stage Andersen Cascade 
Impactor (Copley Scientific Ltd., Nottingham, UK). The flow rate was set to 60 Lmin-1⋅. 
During the process, the aerosol moved along seven stages and according to the diameter and 
density of the particles can be deponated and then it was washed by methanol/phosphate buffer 
(60/40 v/v %) to collect the deposited drug amount. All samples were investigated by UV/VIS 
spectrometry at 271 nm (ATI-UNICAM UV/VIS Spectrophotometer, Cambridge, UK). 
The fine particle fraction (FPF) was established as the number of particles deposited at stage 2 
and lower than 5 µm, divided by the total initial amount of the particles filled in the inhaler (10 
mg). The mass median aerodynamic diameter (MMAD) was defined based on the graph as the 
particle size at which the line crossed the 50th percentile, indicating the particle diameter at 
which 50% of the aerosol particles by mass are larger and 50% are smaller. Drug-emitted dose 
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(ED), defined as the percentage of CIP exiting the DPI, was determined by subtracting the 
amount of CIP remaining in the DPI from the initial mass of CIP loaded. To determine the drug 
content, 10 mg of the ciprofloxacin-bearing spray-dried microparticles was dissolved in 
methanol/phosphate buffer (60/40 v/v %)) and analyzed by UV spectroscopy. 
3.2.10   In vitro release 
To check the difference in drug release between the prepared products, 10 mL of phosphate 
buffer (pH 7.4, as the pH in the lung) was used to suspend an equivalent of 50 mg of CIP 
content in all products. After 1, 2, 3, 4, and 5 min, sample was taken out, filtered, and the 
concentration measured by UV spectroscopy at a maximum wavelength of 271 nm. 
3.2.11   Stress and accelerated stability testing     
Stability tests were performed as recommended by the ICH Q1A Guideline named “(R2) - 
Stability Testing of New Drug Substances and Products”. Stability testing was carried out in a 
Binder KBF 240 (Binder GmbH Tuttlingen, Germany) equipment, with a constant-climate 
chamber. An electronically controlled APT line preheating chamber and refrigerating system 
ensured temperature accuracy and reproducibility of the results in the temperature range 
between 10 and 70 °C and the RH range between 10 and 80 %. Accelerated testing was 
performed at 40 ± 2 ºC with 75 ± 5 % RH. Samples were stored in hard gelatin capsules (size 
3) (Capsugel, Belgium) in open containers; the duration of storage was 6 months. Sampling 
was carried out after 0 and 10 days, and 1, 2, 3 and 6 months. 
3.2.12   Cytotoxicity testing 
For cell culture A549 cells (ATCC, USA), a human immortalized alveolar type II like lung 
epithelial cell line, were cultured. A549 cells (passage number ≤ 35) were grown in Dulbecco’s 
modified Eagle medium supplemented with 10 % fetal bovine serum (FBS, Pan Biotech, 
Germany) and 50 µg/mL gentamicin, in a humidified incubator with 5% CO2 at 37ºC. 
Human endothelial cells derived from cord blood hematopoietic stem cells were cultured in 
endothelial medium (ECM-NG, Sciencell, Carlsbad, CA, USA) supplemented with 5% FBS, 
1% endothelial cell growth supplement (ECGS, Sciencell, Carlsbad, CA, USA), 1% lipid 
supplement (100×, Life Technologies, USA), 550 nM hydrocortisone, 10 µM retinoic acid and 
0.5% gentamycin in a humidified incubator with 5% CO2 at 37ºC. 
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Kinetics of lung epithelial cell reaction to treatment was monitored by impedance measurement 
at 10 kHz (RTCA-SP instrument; ACEA Biosciences, San Diego, CA). Impedance 
measurement is a label-free, real time, noninvasive method, and correlates linearly with 
adherence, growth, number, and viability of cells (Bocsik et al., 2016). For background 
measurements 50 µL cell culture medium was added to the wells, then cells were seeded at a 
density of 5×103 cells/well to rat tail collagen coated 96-well plates with integrated gold 
electrodes (E-plate 96, ACEA Biosciences). Cells were cultured for 4 days and monitored every 
5 min until the end of experiments. At the beginning of plateau phase of growth, cells were 
treated with ciproflaxacin (1, 10, 30, 100 and 300 µM) alone or its formulations prepared with 
leucine, cyclodextrin (CD) and polyvinyl alcohol (PVA) for 48 hours. Triton X-100 detergent 
(10 mg/mL) was used as a reference compound inducing cell toxicity. Cell index was defined 
as Rn-Rb at each time point of measurement, where Rn is the cell-electrode impedance of the 
well when it contains cells and Rb is the background impedance of the well with the medium 
alone. 
3.2.13   Permeability testing 
For the permeability test lung epithelial cells were co-cultured with endothelial cells for ten 
days. Lung epithelial cells were seeded on the upper side of cell culture inserts (Transwell, 0.4 
µm pore size, 1.1 cm2 surface area, Corning Costar Co., MA, USA). coated with rat tail 
collagen. Endothelial cells were passaged to the bottom side of the inserts coated with Matrigel 
(BD Biosciences, Franklin Lakes, NJ, USA). Both cells were cultured in endothelial medium. 
The transepithelial electrical resistance (TEER), representing the permeability of tight 
junctions, was measured on the co-culture model regularly. TEER was measured by an EVOM 
Volt/Ohm Meter (World Precision Instruments, USA) combined with STX-2 electrodes and 
expressed relative to the surface area of the monolayers (Ω cm2). The resistance of cell-free 
inserts was subtracted from the measured values. Before the permeability test the TEER was 
135 ± 11 Ω cm2.  
In the permeability assay cell culture medium was changed in the lower compartment of the 
inserts to 1500 µL Ringer-Hepes solution (118 mM NaCl, 4.8 mM KCl, 2.5 mM CaCl2, 1.2 
mM MgSO4, 5.5 mM d-glucose,10 mM Hepes, pH 7.4) supplemented with 0.1 % bovine serum 
albumin. In the upper compartment culture medium was replaced by 500 µl Ringer-Hepes 
solution containing 10 µM of ciprofloxacin alone or its formulations. To check the monolayer 
integrity three samples were treated with 10 µM FITC-dextran 4.4 kDa (FD4), a permeability 
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marker molecule. The culture plates were kept in a 37 ºC incubator with 5 % CO2 for 30 min 
on a rocking platform. After incubation the concentration of ciprofloxacin in samples from the 
apical and basolateral compartments was determined by HPLC. The concentration of the 
marker molecule FD4 was determined by a fluorescence multi-well plate reader (Fluostar 
Optima, BMG, Labtechnologies, Germany; excitation wavelength: 485 nm, emission 
wavelength: 535 nm). The apparent permeability coefficients (Papp) were calculated as we 
described previously (Kürti, et al 2012). Briefly, cleared volume was calculated from the 
concentration difference of the tracer in the lower/basal compartment (∆[C]B) after 30 min (t) 
and upper/apical compartments at 0 hour ([C]A), the volume of the lower/basal compartment 
(VB; 1.5 mL) and the surface area available for permeability (A; 1.1 cm2) by the Eq. 6: 
[ ]
[ ] tCA
VC
A ××
×
=
BB
(cm/s) Papp  
(6) 
3.2.14   Statistical analysis 
All measurements were completed in triplicate and values are reported as means ±S.D. unless 
otherwise noted. Statistical calculations were performed with the software Statistical for 
Microsoft Windows 7.  To identify statistically significant differences, one-way ANOVA with 
t-test analysis was performed. Probability values of p < 0.05 were considered significant. 
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4. RESULTS 
4.1   QbD methodology and pre-formulation studies of DPI Products 
For pre-formulation firstly an Ishikawa (fishbone) diagram was set up including all the 
parameters influencing the desired DPI product containing CIP as the active agent. The 
parameters were ranked into four groups (Fig. 5), namely 1. material characteristics, 2. 
production method, 3. test methods, and 4. product characteristics. 
 
 
Figure 5: Ishikawa diagram illustrating the parameters influencing the quality of the DPI 
product containing CIP (Karimi et al., 2016) 
This process served as a preliminary knowledge and information collection, which can help in 
the designing of the experiments and the selection of the CQAs and CPPs of the drug 
development procedure. The next step was the selection of the QTPPs, CQAs, and CPPs for 
the aimed DPI product. Table VI lists these with their selected targets and their justification, 
along with the explanations for the classification of the factors selected in each group. 
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Table VI: Selected QTPPs, CQAs, and CPPs of a CIP containing DPI formula, their target, 
justification, and explanation 
        Target Justification/explanation 
QTPPs   
Therapeutic 
indication 
Antibiotic 
(respiratory tract infections) 
Antibacterial therapy is essential in respiratory 
tract infections. Ciprofloxacin is a second -
generation fluoroquinolone antibiotic with a 
broad spectrum of activity. It is especially 
effective against infections caused by Gram-
negative bacteria. 
Target patient 
population 
Adults 
 
Literature data support a wide use of 
fluoroquinolone antibiotics in adults. It is a 
pregnancy category C antibiotic, considered to 
be safe during breastfeeding. It is also allowed 
for pediatric therapy but is never a first-line 
choice. 
Target patient group, as QTPP affects the dose 
selection and the route of administration. 
Route of 
administration Pulmonary administration 
A relatively new route of administration for 
local antibacterial therapy. Pulmonary 
application avoids the first-pass effect, and 
reduces systemic exposure and the risk of side 
effects.  
Site of activity Local effect 
Producing a local effect in pulmonary infections 
allows dose reduction of the antibiotics, 
associated with a lower risk of side effects. 
Pre-selection of the desired site of activity as 
QTPP affects the API used, as well as the dose 
and the dosage form selected. 
Dosage form Dry powder for pulmonary 
use 
Dry powders with a particle size of 2-4 µm are 
required for the optimal deposition in lungs. 
Pre-determination of the adequate dosage form 
is a QTPP according to the ICH Q8 guideline. 
Dissolution 
profile Increased dissolution 
Dissolution profile is a recommended QTPP as 
it affects the bioavailability and 
pharmacokinetics, and is critically related to the 
quality, safety and efficacy of the medicinal 
product. 
CQAs   
Excipients 
(quality profile) 
Excipients assure proper 
quality characteristics by 
modifying the size, 
morphology, 
hydrophility and stability of 
the DPI product. 
Polyvinyl alcohol 3-88 (PVA) is a microfine 
coating material.  
The amino acid L-leucine (LEU) can be well 
co-spray-dried with certain active compounds to 
modify the drug’s aerolization behaviour. 
Dymethyl-beta cyclodextrin (CD) can be 
applied as a drug distribution enhancer. 
As CQAs, excipients are critically related to the 
dissolution and quality profile of the final 
product. 
Particle size 
/specific surface 
area (SSA) 
Homogenous, microsized 
product of 2-4 µm 
Microsize dimension has the optimal specific 
surface area and optimal administration 
properties for pulmonary use. 
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Size is critically related to pulmonary 
administration and to its local and/or systemic 
therapeutic effect, thereby to product safety, 
efficacy and quality. 
Appearance Microparticle 
Microparticle formulation is suitable to achieve 
an increased SSA, an improved wettability and 
a high amount of dissolved drug. 
It is critically related to efficacy. 
Dissolution Improved dissolution rate (100 % in 5 min) 
The dissolution profile highly affects the 
therapeutic effect. Accelerated drug release 
induces an immediate local effect. It is related 
to the modification of the SSA, wettability and 
solubility. 
Wettability Hydrophile product 
Wettability is critical for the drug’s adhesion the 
pulmonary mucosa. It is critically related to 
efficacy. 
Structure (cryst. 
/amorph.) 
Stable form 
(cryst. /amorph) 
The crystalline or the amorphous state of the 
API affects stability and release properties. It is 
critically related to efficacy and quality. 
Solubility Water-soluble  Solubility has a remarkable influence on the bioavailability of the drug/product. 
CPPs   
Composition 
(Co-spray drying) 
Micronized size, stabilized 
structure using additives.  
Additives contribute to reaching the desired and 
pre-defined quality of the final co-spray-dried 
product. 
Inlet 
temperature 
(Co-spray drying) 
130°C 
Inlet temperature has a critical influence on 
optimal drying and thus influences the final 
product’s appearance. 
Outlet 
temperature 
(Co-spray drying) 
75°C 
Outlet temperature has a critical influence on 
optimal drying of the desired co-spray dried 
final product. 
Feed rate 
(Co-spray drying) 5 ml min
-1 Feed rate has a critical influence on the 
formation of co-micronized particles. 
 
Figure 6 shows the elements and results of the QbD based RA. Figure 6A presents the 
interdependence rating of the QTPPs and CQAs, and of the CQAs and CPPs. Each interaction 
was ranked as high (H), medium (M), or low (L). The same three-level scale was used for the 
occurrence rating of the CPPs, which is presented in Figure 6B. These interdependence and 
occurrence ratings were followed by risk estimation calculations using the RA software, which 
produced a precise impact score (or severity score) for each critical influencing parameter. The 
calculated and ranked severity scores for the CQAs and CPPs are presented in Pareto charts 
(Fig. 6C) generated by the software. Pareto charts also give a graphical overview of the 
hierarchy of CQAs and CPPs based on their calculated numerical difference in their influence 
on the aimed quality of the product.  
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Figure 6: Results of (A) the interdependence rating of the QTPPs and CQAs and of the CPPs 
and CQAs, (B) the occurrence rating of the CPPs and (C) Pareto charts of the CQAs and CPPs 
with calculated numeric severity scores generated by the RA software (Karimi et al., 2016) 
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In this special case the particle size (or the specific surface area) of the API is the CQA to have 
the highest impact on the quality of the aimed final product. It is followed by wettability and 
dissolution properties. The next ones are appearance and the excipients’ profile, while primer 
solubility and the structure of the API are found to have the lowest impact. The impact of 
“particle size and SSA” is 41.6% higher than that of “wettability” and is 47.8% and 78.9% 
higher than the impact of “dissolution” and “appearance”, respectively. Comparing “structure” 
and “particle size”, the difference in their impact on the quality of the final product is 183% for 
“particle size”. Among the CPPs product, “composition” was found to have the highest impact 
on the desired final product’s quality. It is followed by the “outlet temperature”, then “inlet 
temperature”, and “feed rate”. The impact of the “composition on product quality” is 29% 
higher than that of “temperature”. Nevertheless, there is a 34% difference between the critical 
process factor with the highest effect (composition) and the lowest effect (feed rate) on the 
final product’s properties. 
These results of the software-based RA highlight those factors that need the highest attention 
during the practical development phase when we decide about the exact composition and select 
the materials and excipients, etc. It has been established that the particle size of the API, the 
wettability and dissolution characteristics, as well as the composition of the DPI product are to 
be focused on during the practical development phase. The different DPI formulations were 
prepared according to these preliminary parameter rankings and priority classifying. 
4.2   Characterization of formulated DPI containing ciprofloxacin hydrochloride 
4.2.1   Solubility of CIP 
Solubility test at different pH as a preliminary experiment was carried out. Table VII shows 
the solubility of ciprofloxacin hydrochloride at different pH and in distilled water. It is 
important to do this test to find out the optimal solubility and consequently the best solvent for 
CIP at different pH. According to the data shown in the Table VII the solubility of CIP is 
reducing in opposite direction to pH reduction. Remarkably, distilled water showed the best 
solubility for CIP. 
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Table VII: Solubility of ciprofloxacin hydrochloride in different pH and distilled water. 
Solvent pH Concentration [mg/ml] 
λ max  
[nm] 
Buffer solution 1.2 12.6 277 
Buffer solution 3.5 36.0 277 
Buffer solution 5.6 13.3 275 
Buffer solution 6.8 0.4 272 
Buffer solution 7.4 6.3 271 
Distilled water 4.4 41.9 275 
 
4.2.2   Micrometric and morphological properties  
 Since all the powders were prepared under similar drying conditions, in the spray-drying 
process the final particle size distributions of the samples were comparable. The smallest 
particle size was measured for the DPI of CIP containing PVA due to covering effect of PVA 
when used as excipient, while the largest value was measured for the DPI of CIP containing 
PVA, LEU, and CD as excipients. This size interval should be optimal for lung deposition, so 
a local treatment of the respiratory tract can be achieved by any of the compositions tested. 
Microparticulate DPIs had a narrow particle size distribution which is highly advantageous for 
pulmonary DPI, because it enables the particles to potently target a specific lung region. In 
consequence, it enables a high deposition of drug particles. Results of the particle size analysis 
are shown in Table VIII. 
Table VIII: Particle size of the microparticles of various compositions prepared 
Material D (0.1) 
 [µm] D (0.5) µm D (0.9) µm 
Specific 
surface area 
[ m2/g] 
CIP_SPD 1.31±0.01 2.44±0.02 4.44±0.01 2.76±0.03 
CIP_PVA_SPD 1.22±0.04 2.38±0.03 4.57±0.03 2.85±0.02 
CIP_CD_SPD 1.68±0.03 3.02±0.06 5.24±0.04 2.20±0.09 
CIP_LEU_SPD 1.62±0.05 2.84±0.02 4.84±0.00 2.33±0.01 
CIP_PVA_CD_LEU_SPD 1.58±0.06 3.27±0.01 6.42±0.02 2.14±0.02 
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Field-emission scanning electron micrographs of the spray-dried microparticles are shown in 
Fig. 7. The DPI of CIP containing PVA has a relatively smooth surface with spherical geometry 
in contrast to the DPI of CIP containing LEU which was found to be cavitated. Such deep 
cavities can also be observed in the DPI containing CD, but those cavities are less deep than 
those in the DPI of CIP containing LEU. The DPI of CIP containing PVA, LEU and CD 
contains no cavities, which may result from the dominant effect of PVA to produce smooth 
surfaces. 
 
Figure 7: Scanning electron micrographs of the spray-dried microparticles (Karimi et al., 
2016) 
4.2.3   Structural characteristics  
A sample containing only raw CIP was prepared by the same method to serve as a reference. 
The thermal response of CIP alone had a broad diffuse endothermic peak at about 145°C 
indicative of recrystallization and a sharp endothermic peak at 312°C indicative of melting.  
In the thermograms of microparticles containing CIP and PVA, characteristic peaks were 
detected. There were two exothermic peaks at 152°C and 190°C due to recrystallization during 
spray-drying, and a sharp endothermic peak was detected at 312°C indicative of melting. 
Interestingly, the microparticles containing CD were shown to have a lower melting point at 
207°C due to their amorphous structure resulting from spray-drying. The microparticles 
containing LEU were shown to have two different endothermic peaks at 270°C and 308°C 
indicating the melting points of LEU and CIP, respectively. Fig. 8 shows the DSC thermograms 
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of raw CIP and of the different CIP-containing microparticles investigated. 
 
Figure 8: Thermograms of raw CIP and of the different CIP-containing microparticles 
investigated (Karimi et al., 2016) 
The XRPD diffractogram of raw CIP shows many characteristic peaks indicating a high degree 
of crystallinity, but the peak with the highest intensity is at 9.09° 2θ area. 
Since the spray-drying parameters were similar for all the formulations, the differences in 
crystallinity must be attributable to the presence of the different excipients. The spray-dried 
products containing excipients exhibit a large degree of amorphicity and a very low degree of 
crystallinity. The only product that shows significant crystallinity is the DPI of CIP containing 
LEU, suggesting that the co-spray dried formulation is composed of crystalline LEU and 
amorphous CIP. Formulations containing CD have a completely amorphous character. The 
characteristic peaks of spray-dried microparticles at 6 2-Theta degree show the tendency of 
CIP to recrystallize from its polymorph. 
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Figure 9: XRPD diffractograms of raw CIP and of the CIP-containing microparticle 
compositions investigated (Karimi et al., 2016) 
The FT-IR spectrum revealed that raw CIP exhibits a peak at 1707 cm-1 as a consequence of 
the cyclic C=O stretching that induces a shift towards the higher wave numbers due to the 
association with the OH groups of other components. The magnitude of the shift in the C=O 
stretching for the bounded dimer form is inversely proportional to the strength of the interaction 
between CIP and the excipients. The other feature detectable at the FT-IR spectrum is the 
widening of the C=O stretching bond, caused by the configuration of the hydrogen realignment 
between the excipients and the C=O bond of ciprofloxacin. The shift of the above bond 
indicates that the interaction between CIP and LEU or PVA is weaker than that between CIP 
and CD. The bands assigned to N-H in the FT-IR spectrum are seen at 1612 cm-1. For the 
microparticles containing excipients several peaks are missing. The peaks at 987cm-1 have 
completely disappeared in all cases due to the change from the dimeric to the monomeric state. 
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The bands assigned to N-H in the FT-IR spectrum can be seen at 1612 cm-1 both in the raw CIP 
and in the spray-dried microparticle compositions. Fig. 10 Shows the FT-IR spectra of the raw 
material and the microparticle compositions investigated. 
 
Figure 10: FT-IR spectra of the raw material and the microparticles (Karimi et al., 2016) 
4.2.4   In vitro characteristics 
Generally, the single CIP_SPD formulation had a low aerosol performance 
(FPF=31.68%±1.43). In contrast, the combined spray-dried formulations containing CIP plus 
excipients exhibited a significantly improved aerosol performance. While even the presence of 
PVA or CD raised the FPF value of the microparticles, those containing LEU were 
characterized by the highest aerosol performance. These results show that the use of excipients 
can significantly improve the aerodynamic behaviour of CIP-containing microparticles. LEU 
has the highest potential to improve the aerosol performance FPF=80.27%±1.65). This value 
indicates that more than 80% of the particles delivered from the inhaler have a volume 
aerodynamic diameter less than 5 µm. Drug contents, FPF, MMAD and ED values are shown 
in Table IX. 
Dissolution tests focused on free CIP release from the samples. Fig. 11 shows ciprofloxacin 
release from the microparticles at pH 7.4. A slower rate of CIP release was observed for the 
spray-dried microparticles containing PVA, compared to those without PVA. This behaviour 
can be interpreted by the controlled release induced by PVA. Drug release was shown to rise 
substantially in the presence of LEU and CD, and microparticles containing LEU as the only 
excipient were shown to be characterized by the highest rate of CIP release, with full API 
release within three minutes. 
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Table Ⅸ: Drug content, fine particle fraction (FPF), mass median aerodynamic diameter 
(MMAD) and emitted dose (ED) of the CIP-containing microparticle compositions investigated 
DPI Drug content (%)  FPF (%)  MMAD (µm) ED (%) 
CIP_SPD         100%±0 31.68%±1.4     7.23±0.01 99.95%±0.5 
CIP_PVA_SPD         85%±0.07 60.18.%±1.3     3.61±0.05 95.92%±0.4 
CIP_CD_SPD         59%±0.03 58.54%±1.1      3.19±0.01 96.93%±0.5 
CIP_LEU_SPD         72%±0.08 80.27%±1.7       2.15±0.08 95.81%±0.6 
CIP_PVA_CD_LEU_SPD        45.%±0.24 45.93%±1.4       4.53±0.02 97.68%±0.4 
 
 
Figure 11.  Kinetic plots of free ciprofloxacin release from the microparticles investigated 
(Karimi et al., 2016) 
 
The different DPI formulations were prepared, and all the particles produced are in acceptable 
particle size for optimal deposition in the lungs. Using PVA as an excipient for the CIP-
containing DPI was shown to decrease the size of the microparticles significantly. The 
application of LEU to the microparticles induced a significant improvement in the FPF and in 
the aerodynamic behavior, and also allows a very fast drug release. Besides the adequate 
formula development, this study confirmed that all the microparticles after spray-drying are in 
amorphous form and it is crucial to study of stability of them further in the process as we did 
that. 
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4.3   Physicochemical stability testing and influence of humidity and temperature on 
aerodynamic properties 
4.3.1   Particle size and morphological analysis 
From particle size analysis aspect, since all the products are in the optimal range of particle 
size for DPI systems (2-5 µm), the studying of particle size during storage is of great 
importance in order to detect which of the products keep the particle size in the optimal range 
until the end of the storage time. The average particle size of single spray-dried CIP during 
storage ranged from 2.44 µm to 2.54 µm and did not show significant difference during storage. 
Specifically, particles in this size range are able to adequately target and reach the deep 
bronchiolar and alveolar regions. The mean diameter of co-spray-dried CIP particles with LEU 
during storage ranged from 2.84 µm to 2.89 µm, which is suitable for targeted inhalation 
delivery as dry powders. In general, after storage median volume diameters of 20.78 ± 0.1 µm 
were observed for the spray-dried CIP with PVA, while values of 51.08 ± 0.1 µm were 
observed for samples containing CD. It means that while the polymer chains interact, they can 
lead to a reduction in physiochemical stabilization due to various potential interactions of the 
polymer chains and their ability to accept diverse conformations. Furthermore, CD can lead to 
an increase in particle size and the agglomeration of particles by reason of complex formation. 
The results also indicate that when the LEU is used in combination with CD or PVA, it exhibits 
a dominant effect and decreases the agglomeration of microparticles, but CD or PVA alone 
exhibits agglomeration and increases the size of microparticles greatly. The results of the 
particle size analysis (D 0.5) are shown in Table X.  
Table Ⅹ: Average particle size of the microparticles of various compositions before and 
during storage 
Samples 
Before  
storage  
[µm] 
10 days 
[µm] 
1 month 
[µm] 
3 months 
[µm] 
6 months 
[µm] 
CIP_SPD 2.44±0.02 2.04±0.03 2.52±0.01 2.57±0.1 2.53±0.6 
CIP_PVA_SPD 2.38±0.03 10.05±0.1 12.15±0.09 15.76±0.9 20.78±0.1 
CIP_LEU_SPD 2.84±0.02 2.82±0.01 2.82±0.04 2.88±0.02 2.89±0.01 
CIP_CD_SPD 3.02±0.06 3.32±0.02 6.22±0.03 7.73±0.05 51.20±0.1 
CIP_PVA_CD_LEU_SPD 3.27±0.01 3.35±0.02 3.36±0.03 3.39±0.02 6.02±0.01 
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From particle form morphology perspective, a representative SEM image of the microparticles 
is shown in Fig. 12. In general, spray-dried microparticles with PVA have a relatively smooth 
surface with spherical geometry, typical of these excipients. During storage this morphology 
is retained but the agglomeration of particles can be observed. This agglomeration can also be 
seen in the microparticles which contain CD, but it is not as substantial as in the case of 
microparticles containing PVA. The use of LEU shows cavitated morphology. The stored 
products maintained the cavitated form, no changes in surface area and aggregation were 
detected. LEU stabilized the morphology and did not undergo any RH-induced changes, 
therefore the taking up of moisture during storage was prevented. The microparticles 
containing CD, LEU and PVA did not exhibit particle aggregation but the microparticles could 
not keep their spherical morphology, which is favorable for the aerodynamic behavior of DPI. 
 
Figure 12: Morphology of the prepared spray-dried samples during the storage (Karimi et al., 
2018) 
 
4.3.2   Structural characterization  
From structural characterization point by XRPD analysis of the samples according to the 
Cambridge Crystallographic Database, there is one crystalline structure of CIP and there are 
two existing polymorphs of ciprofloxacin base, the hydrate and hexahydrate forms. In order to 
investigate the crystallinity, amorphicity and polymorph form of the stored compositions, the 
X-ray powder diffraction method was used. The applied excipients (which are semi crystalline 
or amorphous) and spray-drying could affect the physicochemical properties of CIP. The 
XRPD patterns of the single spray-dried and co-spray-dried powders before and after storage 
are shown in Fig. 13 and the crystallinity fractions of microparticles before and after storage 
are presented in the Table XI. The XRPD diffractogram of spray-dried CIP shows that 
amorphization took place in the sample. After 10 days of storage, the recrystallization of the 
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amorphous form began. By evaluating the diffractograms it can be observed that the amorphous 
microparticles recrystallized to CIP, and during storage no polymorphic changes occurred. The 
crystallinity fraction of the sample before storage was 5.49%, but after 6 months of storage it 
reached 95.76%. This significant and noticeable increase in the crystallinity fraction means that 
CIP has a tendency to fast recrystallization without any crystallinity inhibitor excipient during 
storage. The diffractogram of the sample containing PVA and CIP shows that spray-drying 
resulted in amorphization, but under storage ciprofloxacin recrystallized into its starting 
hydrochloride form. The tendency to recrystallization was lower than without excipient, and 
after 6 months the degree of crystallinity was only 55.81%. Microparticles containing LEU as 
excipient were mostly in amorphous form after spray-drying. After 10 days of storage, the 
characteristic peak of LEU appeared at 5.97° 2θ and the recrystallization of CIP was detected, 
which increased in samples stored for 1, 3 and 6 months and resulted in 98.28% crystalline 
fraction. The microparticles containing CD exhibited amorphization after spray-drying. CD 
protected CIP from fast recrystallization, after 6 months the crystalline content was only 
41.50%. The samples containing PVA, LEU, CD and CIP were amorphous and the tendency 
to recrystallization decreased, only 39.65% crystalline fraction was detected in the sample after 
6 months. 
Table Ⅺ: Crystallinity fraction of microparticles of different products before and after 
storage 
Crystallinity fraction before 
storage 10 days 1 month 3 months 6 months 
CIP_SPD 5.49% 65.17% 90.04% 90.36% 95.76% 
CIP_PVA_SPD 11.38% 29.23% 33.86% 80.20% 95.81% 
CIP_LEU_SPD 21.52% 36.61% 55.50% 82.50% 98.28% 
CIP_CD_SPD 6.30% 7.99% 25.88% 54.57% 81.50% 
CIP_PVA_CD_LEU_SPD 17.75% 18.38% 25.65% 32.76% 39.65% 
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Figure 13: Structural investigation of the products by XRPD before and after storage  
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4.3.3   Thermoanalytical measurements 
From thermo analytical measurements three polymorphic forms of CIP are reported in the 
literature by Kakkar et al 1997, Form I (Tm=313.5°C), Form II, (Tm=312°C) and Form III 
(Tm=316.3°C) [34]. DSC experiments were carried out to investigate the thermal behavior of 
CIP containing microparticles before and during storage (Fig 3.). When analyzing the 
thermogram of the single spray-dried CIP, the starting melting point of CIP at 311.05°C and 
the glass transition temperature at 149.93°C can be detected. Altogether it means spray-drying 
caused amorphization in the sample but some crystallinity fraction was preserved, which 
melted at 311.05°C. Consequently, after 1, 3 and 6 months the crystallinity fraction increased. 
According to the thermogram in Fig. 14 of microparticles containing PVA, amorphization took 
place and the glass transition temperature can be observed at 151.01°C. This exothermic peak 
can be attributed to the recrystallization of amorphous ciprofloxacin at 190.02°C and this 
recrystallized CIP was melted at 312.55°C. However, glass transition after storage cannot be 
detected, which was in good agreement with increasing crystallinity in the compositions. 
Microparticles containing LEU exhibit glass transition at 158.82°C, LEU melts at 271.12°C, 
but the remaining crystallinity structure melts at 313.70°C. After 10 days, stored microparticles 
exhibited an exothermic peak at 182.86°C due to the recrystallization of CIP. The first 
endothermic peak at 270.67°C is the melting point of LEU and the other can be related to CIP 
at 309.72°C. Microparticles containing CD as excipient exhibit glass transition at 138.58°C. 
The melting of CD at 232.3°C was not observed in stored microparticles. 
Microparticles containing PVA, LEU and CD have an exothermic peak at 202.3°C, where 
amorphous ciprofloxacin recrystallized into CIP II form, and an endothermic peak at 232.3°C 
where CD melts. The melting of CIP was not detected. In correlation with the XRPD results it 
was found that amorphous and crystalline form of CIP could be detected in the samples after 
storage. 
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Figure 14: Thermal analyses of fresh samples after 1, 3 and 6 months storage 
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4.3.4   Aerodynamic particle size analysis  
And finally, from most important property of DPI, aerodynamic particle size analysis of the 
microparticles were completed as established by means of the Pharmacopoeia test which is 
mentioned in detail in the Method part. To analyze the effects of excipients on the aerosol 
performance, the advancing deposition of the drugs was calculated. Single CIP_SPD showed 
a FPF value of 31.68 ± 1.4 %, which was enhanced during storage and reached the value of 
67.35 ± 1.1 %. The MMAD of microparticles decreased from 7.23 ± 0.01 to 3.58 ± 0.03 after 
storage. Since single spray-dried CIP does not contain any excipient, it can be explained by the 
loss of water content and lowering the density of microparticles.  In view of literature data, 
LEU is one of the excipients with the ability to enhance aerosol dispersibility, therefore before 
storage the FPF of microparticles containing LEU was 80.27 ± 1.7 % and the MMAD value 
was 3.52 ± 0.13 µm. However, in this experimental work our interest was focused on retaining 
high aerosol dispersibility during storage. After storage, the FPF value and the MMAD value 
of the stored formulations was 79.78±1.22 and 2.01±0.01µm, respectively; (Table XII and 
Table XIII). After storage, the FPF values of the samples did not change significantly. This is 
connected with retaining the particle size and morphology, as discussed before. This cavitated 
morphology and suitable particle size are favorable in terms of the aerosolization performance 
of the formulated DPI.  Before storage, the FPF of microparticles containing CD was 
58.54±1.1, although after storage the FPF values of the samples decreased because of the fine 
particle aggregation. This is associated with the increased particle size and retaining the 
amorphous structure for 3 months. Likewise, PVA did not have strong protecting effect in these 
formulations. As discussed in the previous part, this polymer agent induced aggregation in the 
formulation. Therefore, increasing particle size reduced the FPF of the PVA-containing 
microparticles to 25.00 ± 2.1%. CIP_PVA_CD_LEU_SPD containing microparticles did not 
keep the FPF value, which could be explained by the microparticles losing their spherical 
morphology. In conclusion it was found that soluble CIP consisting of PVA and CD’s 
physiochemical property decline during storage. Aggregation was minimized in formulations 
with LEU and the other two formulations due to the stabilizing effect of LEU, and we continued 
the work (cytotoxicity and permeability test) with this three microparticles which exhibited 
acceptable aerosol performance, while maintaining the FPF during storage. 
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Table XII: FPF value in % of microparticles before and after storage. 
Samples before 
storage 10 days 1 months 3 months 6 months 
CIP_SPD 31.68±1.4 52.98±1.9 54.96±1.4 64.60±2.1 67.35±1.1 
CIP_PVA_SPD 60.18±1.3 56.90±1.5 34.47±2.0 30.86±1.1 25.00±2.1 
CIP_LEU_SPD 80.27±1.7 84.71±1.0 80.21±2.1 77.31±1.9 79.78±1.2 
CIP_CD_SPD 58.54±1.1 47.01±1.3 40.13±1.2 38.21±1.1 36.32±1.3 
CIP_PVA_CD_LEU_SPD 45.93±1.4 48.00±1.1 39.17±1.9 39.00±1.0 28.28±2.3 
 
Table XIII: MMAD value in µm of microparticles before and after storage. 
Samples before 
storage 10 days 1 months 3 months 6 months 
CIP_SPD 7.23±0.01 4.52±0.02 4.31±0.04 3.62±0.01 3.58±0.03 
CIP_PVA_SPD 3.61±0.05 4.10±0.04 7.57±0.03 8.4±0.01 11.18±0.02 
CIP_LEU_SPD 2.15±0.08 2.59±0.02 2.15±0.06 2.67±0.03 2.01±0.01 
CIP_CD_SPD 3.19±0.01 5.30±0.03 6.65±0.02 6.52±0.05 7.52±0.06 
CIP_PVA_CD_LEU_SPD 4.53±0.02 5.47±0.05 6.55±0.03 6.98±0.02 9.11±0.07 
 
This study presented the effects of different excipients (PVA, CD and LEU) during stability 
testing to find the appropriate excipients and stable microparticles to continue the work. 
Accordingly, it was found that CIP aggregation consisting of PVA and CD occurred during 
storage. However, this aggregation was minimized in formulations with LEU regardless of 
presence of other excipients, due to the stabilizing effect of LEU, and the powders exhibited 
acceptable aerosol performance. In conclusion, stability was improved by formulations with 
LEU.  
It should be mentioned that we could also observe appropriate physio-chemical stability in the 
samples spray-dried without any excipients which could be explained by the increasing 
crystallinity. 
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4.4   Determination of cytotoxicity and permeability of spray-dried microparticles into 
epithelial lung cells 
Following the physicochemical stability testing, it was shown that from five different types of 
microparticles three presented acceptable stability (CIP_SPD, CIP_LEU_SPD, 
CIP_LEU_PVA_CD_SPD). Thus, the work was proceeded with these three microparticles. 
4.4.1   Cytotoxicity test 
From cytotoxicity view microparticles contain CIP without excipient and CIP with LEU or 
combinations of excipients did not change the impedance of A549 lung epithelial cell 
monolayers    in the range of 1-300 µM concentrations, indicating no cellular toxicity. Fig. 15 
illustrates Kinetics of lung epithelial cell reaction to treatment with ciprofloxacin at 1, 10, 30, 
100 and 300 µM alone or its formulations prepared with LEU, CD and PVA for 48 hours. 
   
Figure 15: Kinetics of lung epithelial cell reaction to treatment with CIP 
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4.4.2   Permeability test  
The TEER value of the co-culture model was 135 ± 11 Ω cm2 before the permeability study 
and the Papp for the marker molecule, FD4 was 0.9 × 10−6 cm/s in concordance with previous 
results (Walter et al., 2016). No significant difference was found in the permeability value of 
ciprofloxacin compared to its formulation. Fig. 16 explains permeability of CIP (10 µM, 30 
min) and its formulation on a co-culture model of lung epithelium. FD4: FITC-dextran 4.4 kDa, 
permeability marker molecule. Values presented are means ± SEM. Statistical analysis: one-
way analysis of variance followed by Bonferroni posttest. ***P < 0.001, compared to FD4 
treated group, n = 4. 
 
 
Figure 16: Permeability of CIP (10 µM, 30 min) and its formulation on a co-culture model of 
lung epithelium. FD4: FITC-dextran 4.4 kDa, permeability marker molecule. Values presented 
are means ± SEM. Statistical analysis: one-way analysis of variance followed by Bonferroni 
posttest. ***P < 0.001, compared to FD4 treated group, n = 4. 
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5. SUMMARY 
The primary aim of this study was to carry out research relating to the formulation of DPI 
antibiotics. We studied the key features of QbD elements for use in pulmonary delivery system. 
Another objective was to develop a carrier-free, co-spray-dried DPI product containing high 
soluble CIP. 
i. Quality by design (QbD), an up-to-date regulatory-based quality management method, was 
used to predict the final quality of the product. Quality by design (QbD) is a holistic, 
systematic, risk, science and knowledge based method, focusing on extensive preliminary 
design in order to ensure the quality of medicinal products. The basis of this thinking is 
described in the guidelines of the International Council for Harmonization of Technical 
Requirements for Pharmaceuticals for Human Use (ICH). It has been established that the 
particle size of the API, the wettability and dissolution characteristics, as well as the 
composition of the DPI product are to be focused on during the practical development 
phase. According to the QbD-based theoretical preliminary parameter ranking and priority 
classification, DPI formulation tests were successfully performed in practice. The different 
DPI formulations were prepared according to these preliminary parameter rankings and 
priority classifications. 
ii. According to significant solubility of CIP in distilled water we decided to use it as the 
solvent for feeding solution Spray drying showed to be a trustworthy technique to produce 
CIP microparticle. Then dry powder formulations were prepared and examined by particle 
size analysis, scanning electron microscopy, Fourier-transform infrared spectroscopy, X-
ray powder diffraction, differential scanning calorimetry, and in vitro drug release and 
aerodynamic particle size analyses were also performed. The different DPI formulations 
were prepared, and all the particles produced are in acceptable particle size for optimal 
deposition in the lungs. Using PVA as an excipient for the CIP-containing DPI was shown 
to decrease the size of the microparticles significantly. The application of LEU to the 
microparticles induced a significant improvement in the FPF and in the aerodynamic 
behavior, and also allows a very fast drug release. These formulations displayed an 
enhanced aerosol performance with fine particle fraction up to 80%. 
iii. Besides the adequate formula development, this study confirmed that all the microparticles 
after spray-drying are in amorphous form and it is crucial to study of stability of them 
further in the process as we did that. The next step of this work was to test the stability of 
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co-spray dried CIP. Since the microparticles in the dry powder system do not contain any 
stabilizer, the effects of temperature and RH on the physicochemical properties and 
aerosolization behavior are investigated. Hence investigation of the role of excipients such 
as PVA, LEU and CD on physicochemical stability and aerosolization performance is 
essential element prior designing the final dosage form. Particle characterization and size 
measurement as the most important parameters in aerodynamic behavior were examined. 
The overall stability results (against RH and temperature) showed that microparticles 
containing CIP and LEU alone and in combination with the other excipients were more 
stable than those containing PVA or CD alone. In relation to fine particle fraction and mass 
median aerodynamic diameter (determining the aerosolization parameters), it was found 
that the particle size and particle shape did not show significant changes after the storage. 
Among the excipients LEU was found to have many advantages, including relatively 
simple formulation, enhanced aerosolization behavior, convenient portability and 
inherently improved stability. 
iv. Following the physicochemical stability testing, it was shown that from five different types 
of microparticles three presented acceptable stability (CIP_SPD, CIP_LEU_SPD, 
CIP_LEU_PVA_CD_SPD). Thus, the work was proceeded with these three 
microparticles. For cytotoxicity test firstly cell culture human immortalized alveolar type 
II like lung epithelial cell line like, were done. From cytotoxicity view microparticles 
contain CIP without excipient and CIP with LEU or combinations of excipients did not 
change the impedance of A549 lung epithelial cell monolayers in the range of 1-300 µM 
concentrations, indicating no cellular toxicity As a result, microparticles did not change 
the impedance of lung epithelial cell and did not show any cellular toxicity. For the 
permeability test lung epithelial cells were co-cultured with endothelial cells for ten days. 
From permeability perspective formulations have same permeability value compared to 
CIP formulations. 
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6. NOVELTY AND PRACTICAL ASPECTS 
This study has created the ability of development of DPI and spray-drying techniques to 
produce microparticles containing CIP for pulmonary drug delivery. The development of DPI 
of antibiotics in carrier- free system is a novelty for local treatment of respiratory tract infection. 
• In this current work the application of an up-to-date and regulatory-based pharmaceutical      
quality management method demonstrated as a new development concept in the process 
of formulating DPI. This formulation produced according to the QbD methodology and 
Risk Assessment thinking. This innovative formulation technology and product appear to 
have a great potential in pulmonary drug delivery. Subsequent to no examples of QbD and 
RA based CIP containing DPI system formulation have been described so far. 
• Co-spray-drying of CIP from an aqueous solution as innovative technology was used to                    
prepare the novelty-type of microparticles. The advanced technology was prepared the 
formulation of CIP in one-step and fast process. The final microparticles which developed 
in green technology ensures the respirable particle size range (3-5 µm), with spherical 
morphology. The microparticles displayed an enhanced aerosol performance with fine 
particle fraction up to 80%. This high ability to aerosolization of particles is uniqueness in 
the DPI development. 
• The formulated microparticles as innovative product tested for the stability in stress and 
accelerated test in long term (6 months). Since the microparticles in the dry powder system 
are amorphous and do not contain any stabilizer, the results of this test are very important. 
The stable product which may be considered suitable for scaled-up processes and 
pulmonary application. 
• The formulated DPI illustrate a novel possibility in treatment of respiratory tract infection 
and the innovative technology and product present to be of great potential in pulmonary 
drug delivery systems. 
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